Dollars for Donuts: Inside the Key Elements of PhRMA's Health Reform Deal
This article was originally published in RPM Report
The key part of PhRMA's deal with the Finance Committee is a double win for industry: assuring that closing the donut hole will be part of reform, and that PhRMA will get credit for a big part of the savings.
You may also be interested in...
The Congressionally-chartered Medicare Payment Advisory Commission is preparing a formal endorsement of a plan to overhaul Part D. It will come just in time to help move stalled legislation – and that legislation may be the best chance the drug industry has to fend off draconian pricing measures in 2021.
The Obama Administration OKs the use of co-pay cards for brand prescription drugs in the ACA-created insurance exchanges. One prominent Republican intends to investigate the decision. But insurers and PBMs can decide whether or not to accept them—a fact being lost in the debate.
A Kaiser Family Foundation report on the impact of the Medicare Part D donut hole reads like an artifact of history. But it helps quantify the benefit to brand name industry from closing the donut hole in the context of health care reform.